<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>
   <italic>LRRK2</italic>-targeted treatments including LRRK2 inhibitors and antisense oligomeres under development for PD
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="7">LRRK2</th>
   </tr>
   <tr>
    <th>Compound</th>
    <th>DNL201</th>
    <th>DNL151</th>
    <th>No public data</th>
    <th>No public data</th>
    <th>No public data</th>
    <th>BIIB094</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Sponsor</td>
    <td>Denali</td>
    <td>Denali</td>
    <td>GSK</td>
    <td>Pfizer</td>
    <td>Genetech</td>
    <td>Biogen</td>
   </tr>
   <tr>
    <td>RCT no.</td>
    <td>NCT03710707</td>
    <td>NCT04056689</td>
    <td/>
    <td/>
    <td/>
    <td>NCT03976349</td>
   </tr>
   <tr>
    <td>Mechanism</td>
    <td>LRRK2 inhibition</td>
    <td>LRRK2 inhibition</td>
    <td>LRRK2 inhibition</td>
    <td>LRRK2 inhibition</td>
    <td>LRRK2 inhibition</td>
    <td>Antisense oligonucleotide (ASO)</td>
   </tr>
   <tr>
    <td>Status</td>
    <td>Completed</td>
    <td>Delayed because of COVID19</td>
    <td>Planned</td>
    <td>Under development</td>
    <td>Under development</td>
    <td>Ongoing, estimated completion end of 2022</td>
   </tr>
   <tr>
    <td>Phase</td>
    <td>Phase 1b</td>
    <td>Phase 1b</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>Phase 1</td>
   </tr>
   <tr>
    <td>Design</td>
    <td>Multicenter, randomized, placebo-controlled</td>
    <td>Multicenter</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>International, multicenter, placebo-controlled</td>
   </tr>
   <tr>
    <td>Total 
     <italic>N</italic> of patients
    </td>
    <td>29</td>
    <td>34</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>62</td>
   </tr>
   <tr>
    <td>
     <italic>LRRK2</italic>-PD
    </td>
    <td>√</td>
    <td>√</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>√</td>
   </tr>
   <tr>
    <td>Idiopathic PD</td>
    <td>√</td>
    <td>√</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>√</td>
   </tr>
   <tr>
    <td>Age</td>
    <td>30–75</td>
    <td/>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>35–80</td>
   </tr>
   <tr>
    <td>Duration</td>
    <td>28 days</td>
    <td>28 days</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n.d.</td>
   </tr>
   <tr>
    <td>Doses tested</td>
    <td>Low/high</td>
    <td>Three doses</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>n/a</td>
    <td>Single- and multiple-ascending-dose</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
